Transenterix Inc (NYSE:TRXC) had its target price hoisted by research analysts at Stifel Nicolaus from $3.75 to $4.00 in a note issued to investors on Tuesday. The brokerage presently has a “buy” rating on the medical instruments supplier’s stock. Stifel Nicolaus’ target price would suggest a potential upside of 35.14% from the stock’s current price.
WARNING: “Transenterix Inc (TRXC) PT Raised to $4.00 at Stifel Nicolaus” was originally reported by Sports Perspectives and is the sole property of of Sports Perspectives. If you are accessing this report on another domain, it was illegally copied and republished in violation of US and international copyright law. The legal version of this report can be viewed at https://sportsperspectives.com/2017/11/02/transenterix-inc-trxc-pt-raised-to-4-00-at-stifel-nicolaus.html.
TransEnterix, Inc is a medical device company. The Company is focused on the development and commercialization of ALF-X Surgical Robotic System (the ALF-X System), and SurgiBot System. The Company’s ALF-X System is a multi-port robotic surgery system, which allows multiple robotic arms to control instruments and a camera.
Receive News & Ratings for Transenterix Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Transenterix Inc and related companies with MarketBeat.com's FREE daily email newsletter.